Q1 2026 Financial Performance - Service revenue reached $1763 million, representing a 2% year-over-year growth[39, 40, 42] - Total revenue amounted to $1814 million, showing a 2% year-over-year increase[39, 40, 42] - GAAP operating margin stood at 03%[39] - Non-GAAP operating margin was 9%[39, 40] - Cash flow from operations was $12 million[39] - Cash, equivalents, and restricted cash totaled $82 million at quarter-end[39] Business Highlights - Voice AI Interactions increased more than 7x from Q1 2025[35] - Annual revenue from customers with 3 or more products now represents more than one-third of annual revenue, excluding consumption revenue[35] Future Guidance - Q2 2026 service revenue is projected to be between $170 million and $175 million, with a growth rate ranging from -29% to 00% year-over-year[61] - Q2 2026 total revenue is expected to be between $175 million and $180 million, with a growth rate ranging from -33% to -06% year-over-year[61] - FY 2026 service revenue is projected to be between $685 million and $700 million, with a growth rate ranging from -11% to 10% year-over-year[63] - FY 2026 total revenue is expected to be between $706 million and $720 million, with a growth rate ranging from -13% to 07% year-over-year[63]

Financial Performance & Guidance - Second quarter 2025 CAFD reached $152 million, impacted by lower renewable resource[13] - The company is updating its 2025 CAFD guidance range to $405-440 million, raising the bottom end due to closed 3rd party M&A[13,40] - The company is targeting CAFD per share to $2.50-2.70 in 2027, increased from $2.40-2.60 previously[13] - The company expects to generate over $270 million of retained CAFD cumulatively between 2025-2027 and to have over $600 million of debt capacity to fund growth[44] Growth Initiatives - The company announced a dividend increase of 1.6% to $0.4456/share in 3Q25, or $1.7824/share annualized[13] - Mt Storm repowering is set to begin in 2H25, completed in two phases in 2026 and 2027, with estimated corporate capital of ~$220-230 million and a target 5-year average incremental annual asset CAFD yield of ~11-13%[13,19] - The company signed a 15-year PPA for Goat Mountain repowering with a hyperscaler customer, targeting a 2027 COD, with estimated corporate capital of ~$200 million and a target 5-year average incremental annual asset CAFD yield of +10%[13,19] - The company received an offer to invest in a 291 MW battery storage portfolio, requiring ~$65 million of estimated corporate capital[13] - The company closed a 3rd party M&A agreement for the operational Catalina Solar project, requiring ~$122 million of estimated corporate capital[13] Pipeline & Future Growth - The late-stage pipeline through 2029 vintages has over $1.5 billion of potential corporate capital investments beyond already offered/committed projects/advanced repowerings[32] - Clearway Group has 9.4 GW of late-stage projects through the end of the decade[13,60]

Financial Performance - Comscore's Q2 2025 revenue reached $89.4 million, a 4% increase year-over-year[7, 14] - Adjusted EBITDA for Q2 2025 was $8.9 million, a 25% increase year-over-year[7, 19] - Cross-Platform products experienced substantial growth, with a 60% increase in Q2[7] - Content & Ad Measurement Solutions revenue increased by 6% year-over-year[15] - Research & Insight Solutions revenue decreased by 7% year-over-year due to lower renewals and timing of delivery for certain custom digital products[16] Growth Drivers and Strategy - Growth is expected in Cross-Platform and Linear Currency products[8] - The company anticipates single-digit growth overall[9] - The company expects over 35% growth in Linear Currency[9] - The company is innovating to deliver durable cross-platform value across the $400B+ media ecosystem[12] Guidance - The company maintains full-year revenue guidance at $360-370 million[22, 23] - The company maintains adjusted EBITDA margin rate guidance of 12-15%[22]

Q4 FY2025 Earnings Presentation August 5, 2025 Safe Harbor This presentation and the investor call to which it relates contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, such as statements about FY2028 targets, forecast, guidance, product offering, capital expenditures, the funding environment, seasonality, and trends (including in enrollment). All statements other than statements of historic ...

Second Quarter 2025 Earnings Conference Call August 5, 2025 LGTMs: Date: Andrew T. (Input) Verbal LGTM 8/1 Peter K. LGTM 8/1 af Legal (Karen / Peter R.) LGTM 8/4 Accounting (#s confirm) LGTM (7/31 - Joe) Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.'s ("Clover Health," "we," "our," or "us") expectations regarding Adjusted EBITDA, Adjusted Net income ...

Financial Performance - Revenue reached $442 million, a 21% year-over-year increase[4,9] - Non-GAAP gross margin was 38.1%, showing a sequential increase[4,9] - Non-GAAP EPS was $1.50, up 76% year-over-year[4,9] - Operating cash flow was $47 million[4] - Total cash was $714 million[4] Revenue Breakdown by Market - Semiconductor Equipment revenue was $209.5 million, up 11.3% year-over-year[17] - Industrial & Medical revenue was $68.6 million, down 13.3% year-over-year[17] - Data Center Computing revenue was $141.6 million, up 94% year-over-year[17] - Telecom & Networking revenue was $21.8 million, down 11% year-over-year[17] Future Outlook - The company forecasts approximately 17% total revenue growth for 2025[7] - Data Center Computing revenue is projected to grow more than 80% in 2025[9] - Q3 2025 revenue guidance is $440 million ± $20 million[21] - Q3 2025 non-GAAP EPS guidance is $1.45 ± $0.25[21]

Financial Performance - MRD revenue reached $49.9 million, a 42% year-over-year increase[6] - Excluding milestones, MRD revenue grew by 38% year-over-year[6] - Total revenue increased by 36% to $58.9 million[31] - Sequencing gross margin increased to 64%, up 14 percentage points year-over-year[6] - The company's cash position is strong at $222 million[6] - Q2 2025 cash burn was approximately $11 million, a 36% decrease compared to Q2 2024[6] MRD Business - Clinical testing revenue increased by 57% year-over-year in Q2 2025[9] - clonoSEQ US volume reached 24,624 tests in Q2 2025[10] - 44% of MRD tests were conducted in blood in Q2 2025[11] - MRD pharma backlog is approximately $218 million, a 21% year-over-year growth[19]

Financial Performance & Strategy - Pacira reported Q2 2025 total revenue of $181 million[42] - The company is transitioning into an innovative biopharmaceutical organization, aiming to lead in musculoskeletal pain and adjacencies[5] - Pacira updated its 2025 total revenue guidance to $730-750 million[42] - Non-GAAP gross margins were 82% in Q2 2025[42], with a new range projected at 78-80%[10] - Adjusted EBITDA for Q2 2025 was $54 million[42] - The company has approximately $270 million in cash and investments[41,42] Product & Pipeline Development - Over 3 million patients are treated per year with Pacira's products[4] - EXPAREL's intellectual property is strengthened with two new patents listed in the FDA's Orange Book, providing exclusivity into 2040+[16] - Two registrational studies for ZILRETTA in shoulder OA and iovera° in spasticity are progressing as planned[20] - The Phase 2 ASCEND Part A study for PCRX-201 has surpassed 50% enrollment[22] Market Access & Commercial Growth - Over 40 million commercial lives have access to EXPAREL via separate reimbursement as of Q2 2025[29], with ~100 million total covered lives expected by year end[29] - The company signed a 3rd GPO in Q2 2025, increasing procedural volumes of EXPAREL business under contract[31]

Company Overview - LifeMD is building a leading platform for comprehensive virtual healthcare[7] - The company has conducted 13 million virtual consults and has 297000 active patients[8] - LifeMD's revenue guidance for 2025 is between $250 million and $255 million[8] - The company has over 300 employees across the US[8] Investment Highlights - LifeMD forecasts $27 million to $29 million of Adjusted EBITDA for 2025[12] - The company's products and services generate 85%+ consolidated gross margins[12] - WorkSimpli, in which LifeMD holds a 73% equity stake, provides high-margin recurring revenue[9, 12] Financial Performance and Guidance - LifeMD forecasts 20% revenue growth in 2025, with revenue reaching $255 million[42] - Telehealth revenue is projected to grow by 23% to 27%, reaching $195 million to $200 million in 2025[50] - WorkSimpli is expected to generate $55 million in revenue in 2025, a 2% increase[50] - Consolidated Adjusted EBITDA is projected to increase by 93% to 107%, reaching $27 million to $29 million in 2025[50]

Financial Performance - Total revenue for Q2 2025 reached $189 million, representing a 21% year-over-year growth[8, 43] - Adjusted EBITDA for Q2 2025 was $57 million, resulting in a 30% margin[43] - The company has no long-term debt[43] Revenue Growth Drivers - Scaling new advertisers contributed to approximately one-third of the first half of 2025 revenue growth, with 1 percentage point of the 19% revenue growth coming from 2024 Moat advertiser wins[8] - Activation revenue grew by 25% year-over-year in Q2 2025[33] - Measurement revenue increased by 15% year-over-year in Q2 2025[33] - Supply-side revenue experienced a 26% year-over-year growth in Q2 2025[33] Strategic Initiatives - The company is focused on an "Attach, Stack and Scale" revenue strategy, emphasizing verification measurement expansion and activation product upsells[9, 10] - The company is expanding coverage across Retail Media Networks, with total supply-side revenue growth of 26% and retail media supply-side growth of 39% in Q2 2025[26, 28, 29] Market Expansion - Social measurement revenue grew 14% year-over-year in Q2 2025[19] - CTV measurement impressions grew 45% year-over-year in Q2 2025[21]